These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38403067)

  • 41. Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia.
    Suzuki H; Tsutsumi T; Kawaguchi M; Amano K; Kawaguchi T
    Clin Mol Hepatol; 2024 Jul; 30(3):577-579. PubMed ID: 38447531
    [No Abstract]   [Full Text] [Related]  

  • 42. Prevalence and risk factors of fatty liver in Portuguese adults.
    Leitão J; Carvalhana S; Cochicho J; Silva AP; Velasco F; Medeiros I; Alves AC; Bourbon M; Oliveiros B; Rodrigues V; Sousa R; Sampaio F; Carvalho A; Cortez-Pinto H
    Eur J Clin Invest; 2020 Jun; 50(6):e13235. PubMed ID: 32289180
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease.
    Tsutsumi T; Nakano D; Kawaguchi M; Takahashi H; Kawaguchi T
    Clin Mol Hepatol; 2024 Apr; 30(2):266-268. PubMed ID: 38471499
    [No Abstract]   [Full Text] [Related]  

  • 44. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis.
    Rich NE; Oji S; Mufti AR; Browning JD; Parikh ND; Odewole M; Mayo H; Singal AG
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):198-210.e2. PubMed ID: 28970148
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-Alcoholic Fatty Liver Disease and Vascular Disease.
    Forlano R; Mullish BH; Nathwani R; Dhar A; Thursz MR; Manousou P
    Curr Vasc Pharmacol; 2021; 19(3):269-279. PubMed ID: 32188385
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Emphasis on clinical study of heterogeneity of non-alcoholic fatty liver disease].
    Huang LJ; Xu YH; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2020 Mar; 28(3):193-197. PubMed ID: 32306650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease.
    Min Y; Wei X; Wei Z; Song G; Zhao X; Lei Y
    Cardiovasc Diabetol; 2024 Jun; 23(1):188. PubMed ID: 38824550
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High prevalence of non-alcoholic fatty liver disease in patients with a first episode of acute ischemic stroke. Impact on disability and death.
    Canillas L; Soriano-Varela A; Rodríguez-Campello A; Giralt-Steinhauer E; Cuadrado-Godia E; Broquetas T
    Front Endocrinol (Lausanne); 2022; 13():1003878. PubMed ID: 36589812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Debate--A bridge too far: Nonalcoholic fatty liver disease will not exhaust the donor pool.
    O'Leary JG
    Liver Transpl; 2014 Nov; 20 Suppl 2():S38-41. PubMed ID: 25164795
    [No Abstract]   [Full Text] [Related]  

  • 50. Association between obesity phenotypes and non-alcoholic fatty liver: a large population- based study.
    Najafi F; Pasdar Y; Nazar MM; Darbandi M
    BMC Endocr Disord; 2024 Jun; 24(1):96. PubMed ID: 38918729
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A "systems medicine" approach to the study of non-alcoholic fatty liver disease.
    Petta S; Valenti L; Bugianesi E; Targher G; Bellentani S; Bonino F; ;
    Dig Liver Dis; 2016 Mar; 48(3):333-42. PubMed ID: 26698409
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
    Wu T; Ye J; Mo S; Ye M; Li X; Li Q; Wang W; Zheng Q; Luo K; Zhang Y; Tu S; Che D; Gong R; Chen X; Miu R; Shao C; Sun Y; Zhong B
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1636-1647. PubMed ID: 38695344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease.
    Rinella ME; Castro Narro GE; Krag A; Terrault N; Newsome PN
    J Hepatol; 2024 Jul; 81(1):e20-e21. PubMed ID: 38906627
    [No Abstract]   [Full Text] [Related]  

  • 54. Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature.
    ; ; ; ; ; ; ;
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1190-1196. PubMed ID: 38529849
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
    Vernon G; Baranova A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017.
    Kim D; Adejumo AC; Yoo ER; Iqbal U; Li AA; Pham EA; Cholankeril G; Glenn JS; Ahmed A
    Gastroenterology; 2019 Oct; 157(4):1055-1066.e11. PubMed ID: 31251928
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Accurate prediction of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease using electronic health records.
    Drozdov I; Szubert B; Rowe IA; Kendall TJ; Fallowfield JA
    Ann Hepatol; 2024; 29(5):101528. PubMed ID: 38971372
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-alcoholic Fatty Liver Disease in Children.
    Muzurović E; Polyzos SA; Mikhailidis DP; Borozan S; Novosel D; Cmiljanić O; Kadić N; Mantzoros CS
    Curr Vasc Pharmacol; 2023; 21(1):4-25. PubMed ID: 36411561
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA.
    Rich NE; Noureddin M; Kanwal F; Singal AG
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):422-424. PubMed ID: 34015351
    [No Abstract]   [Full Text] [Related]  

  • 60. Metabolic factors affecting hepatocellular carcinoma in steatohepatitis.
    Zarrinpar A; Faltermeier CM; Agopian VG; Naini BV; Harlander-Locke MP; Kaldas FM; Farmer DG; Busuttil RW
    Liver Int; 2019 Mar; 39(3):531-539. PubMed ID: 30427105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.